1019 related articles for article (PubMed ID: 17242925)
1. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
2. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
[TBL] [Abstract][Full Text] [Related]
4. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
Jordan S; Koprivica V; Chen R; Tottori K; Kikuchi T; Altar CA
Eur J Pharmacol; 2002 Apr; 441(3):137-40. PubMed ID: 12063084
[TBL] [Abstract][Full Text] [Related]
5. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
Jordan S; Chen R; Koprivica V; Hamilton R; Whitehead RE; Tottori K; Kikuchi T
Eur J Pharmacol; 2005 Jul; 517(3):165-73. PubMed ID: 15985260
[TBL] [Abstract][Full Text] [Related]
6. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
7. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
Newman-Tancredi A; Rivet JM; Cussac D; Touzard M; Chaput C; Marini L; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):188-99. PubMed ID: 12923612
[TBL] [Abstract][Full Text] [Related]
9. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus.
Bermack JE; Haddjeri N; Debonnel G
J Pharmacol Exp Ther; 2004 Aug; 310(2):578-83. PubMed ID: 15044555
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
11. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
12. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
Zhang JY; Kowal DM; Nawoschik SP; Lou Z; Dunlop J
Biochem Pharmacol; 2006 Feb; 71(4):521-9. PubMed ID: 16336943
[TBL] [Abstract][Full Text] [Related]
13. In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus.
El Mansari M; Blier P
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jan; 376(5):351-61. PubMed ID: 18060386
[TBL] [Abstract][Full Text] [Related]
14. SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
Scott C; Soffin EM; Hill M; Atkinson PJ; Langmead CJ; Wren PB; Faedo S; Gordon LJ; Price GW; Bromidge S; Johnson CN; Hagan JJ; Watson J
Eur J Pharmacol; 2006 Apr; 536(1-2):54-61. PubMed ID: 16571351
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
16. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
Marona-Lewicka D; Nichols DE
Psychopharmacology (Berl); 2004 Apr; 172(4):415-21. PubMed ID: 14647959
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
[TBL] [Abstract][Full Text] [Related]
20. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
